An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine

Leonel Maldonado; Mariana Brait; Christina Michailidi; Enrico Munari; Tina Driscoll; Luciana Schultz; Trinity Bivalacqua; Mark Schoenberg; David Sidransky; George J. Netto; Mohammad Obaidul Hoque

doi:10.18632/oncotarget.2129

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine

Leonel Maldonado, Mariana Brait, Christina Michailidi, Enrico Munari, Tina Driscoll, Luciana Schultz, Trinity Bivalacqua, Mark Schoenberg, David Sidransky, George J. Netto and Mohammad Obaidul Hoque _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2014; 5:5218-5233. https://doi.org/10.18632/oncotarget.2129

Metrics: PDF 1853 views | HTML 3556 views | ?

Abstract

Leonel Maldonado1,5,*, Mariana Brait1,*, Christina Michailidi1, Enrico Munari1,2, Tina Driscoll3, Luciana Schultz2, Trinity Bivalacqua3, Mark Schoenberg3, David Sidransky1, George J. Netto2,3 and Mohammad Obaidul Hoque1,3,4

1 Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

2 Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA

3 Department of Urology, Johns Hopkins University, Baltimore, Maryland, USA

4 Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA

5 Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

* These authors contributed equally to this work

Correspondence:

Mohammad Obaidul Hoque, email:

George J Netto, email:

Keywords: LGPUCC, Recurrence, Epigenetics, Biomarkers, DNA methylation

Received: January 21, 2014 Accepted: June 22, 2014 Published: June 23, 2014

Abstract

By a candidate gene approach, we analyzed the promoter methylation (PM) of 8 genes (ARF, TIMP3, RAR-β2, NID2, CCNA1, AIM1, CALCA and CCND2) by quantitative methylation specific PCR (QMSP) in the DNA of 17 non-recurrent and 19 recurrent noninvasive low grade papillary urothelial cell carcinoma (LGPUCC) archival tissues. Among the genes tested, by establishing an empiric cutoff value, CCND2, CCNA1, NID2, and CALCA showed higher frequency of methylation in recurrent than in non-recurrent LGPUCC: CCND2 10/19 (53%) vs. 2/17 (12%) (p=0.014); CCNA1 11/19 (58%) vs. 4/17 (23.5%) (p=0.048); NID2 13/19 (68%) vs. 3/17 (18%) (p=0.003) and CALCA 10/19 (53%) vs. 4/17 (23.5%) (p=0.097), respectively. We further analyzed PM of CCND2, CCNA1, and CALCA in urine DNA from UCC patients including LGPUCC and controls. The frequency of CCND2, CCNA1, and CALCA was significantly higher (p<0.0001) in urine of UCC cases [38/148 (26%), 50/635%) respectively] than controls [0/56 (0%), 10/60 (17%) and 16/56 (28.5%), respectively)]. Most importantly we found at least one of the 3 markers were methylated positive in 25 out of 30 (83%) cytology negative LGPUCC cases. We also explored the biological function of CCNA1 in UCC. Prospective confirmatory studies are needed to develop a reliable tool for prediction of recurrence using primary LGPUCC tissues and/or urine.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2129

Publication Alerts

Clinical Research Papers:

An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine

Abstract